Is acalatinib/acalatinib capsule a targeted drug?

Acalatinib/Acalatinib capsule is a targeted drug. Targeted drugs refer to drugs or their preparations that are endowed with targeting capabilities. The purpose is to enable the drug or its carrier to target a specific lesion site and accumulate or release active ingredients at the target site. Targeted preparations can make the drug form a relatively high concentration in the target area, thereby improving the efficacy of the drug while suppressing toxic side effects and reducing damage to normal tissues and cells.

Acalatinib/Acalatinib capsule is a highly selective Bruton's tyrosine kinase (BTK) inhibitor and is a targeted drug. It can covalently bind to BTK and inhibit its activity, thereby blocking the B cell signaling pathway and reducing the incidence of leukemia and other diseases. This drug is particularly suitable for adults with mantle cell lymphoma (MCL) who have received at least one previous therapy, providing them with a new treatment option.

Acalabrutinib/The efficacy of acalabrutinib capsules has been fully verified in clinical trials. For example, acotinib showed significant efficacy in a global clinical study of adults with MCL who had received at least one prior therapy. It is also relatively safe, with relatively few and mild side effects. Common side effects include headache, diarrhea, bruises, skeletal and muscle pain, etc., but they are usually controllable. This allows patients to better tolerate treatment and adhere to their medication.

, Acalatinib/Acalatinib capsule is a targeted drug that exerts a therapeutic effect by inhibiting the activity of BTK. Its efficacy and safety are supported by clinical studies, providing new treatment options for patients with diseases such as mantle cell lymphoma. As a targeted drug, acalabrutinib can act more precisely on the lesion, improve drug efficacy and reduce toxic and side effects, which is of great significance to improving patients' quality of life and prolonging survival.